MX2020008446A - Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. - Google Patents

Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.

Info

Publication number
MX2020008446A
MX2020008446A MX2020008446A MX2020008446A MX2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A
Authority
MX
Mexico
Prior art keywords
antibodies
treating cancer
methods
binding fragment
ctla4
Prior art date
Application number
MX2020008446A
Other languages
English (en)
Spanish (es)
Inventor
Rachel Allison Altura
Mallika Lala
Lokesh Jain
Mengyao Li
Archie Ngai-Chiu Tse
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2020008446A publication Critical patent/MX2020008446A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020008446A 2018-02-13 2019-02-08 Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. MX2020008446A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862630038P 2018-02-13 2018-02-13
US201862732828P 2018-09-18 2018-09-18
US201862740741P 2018-10-03 2018-10-03
PCT/US2019/017188 WO2019160755A1 (en) 2018-02-13 2019-02-08 Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies

Publications (1)

Publication Number Publication Date
MX2020008446A true MX2020008446A (es) 2020-09-28

Family

ID=67620098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008446A MX2020008446A (es) 2018-02-13 2019-02-08 Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.

Country Status (11)

Country Link
US (1) US20210047409A1 (https=)
EP (1) EP3752193A4 (https=)
JP (2) JP2021513540A (https=)
KR (1) KR20200119845A (https=)
CN (2) CN119792515A (https=)
AU (2) AU2019222517A1 (https=)
BR (1) BR112020015915A8 (https=)
CA (1) CA3090996A1 (https=)
MA (1) MA51844A (https=)
MX (1) MX2020008446A (https=)
WO (1) WO2019160755A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
EP3937979A4 (en) * 2019-03-13 2023-03-08 Merck Sharp & Dohme LLC COMBINATIONAL ANTI-CANCER THERAPIES WITH CTLA-4 AND PD-1 BLOCKING AGENTS
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
EP4114863A4 (en) * 2020-03-05 2024-04-24 Merck Sharp & Dohme LLC METHODS OF TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY AND AN ANTI-TIGIT ANTIBODY
EP4114464A4 (en) * 2020-03-05 2024-05-01 Merck Sharp & Dohme LLC Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof
WO2021213523A1 (zh) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
TW202305009A (zh) * 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
MX2024000406A (es) * 2021-07-19 2024-04-18 Regeneron Pharma Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer.
CN118176021A (zh) * 2021-10-29 2024-06-11 昂科医药 抗ctla-4抗体给药方案
CN113933520B (zh) * 2021-11-15 2023-06-20 邹灵龙 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒
WO2024002074A1 (zh) * 2022-06-28 2024-01-04 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
WO2024055005A2 (en) * 2022-09-09 2024-03-14 Adagene Pte. Ltd. Activatable anti-ctla4 antibodies for treating cancer
AU2024251723A1 (en) * 2023-04-10 2025-11-27 Akeso Pharma Co., Ltd. Medical use of anti-ctla4 and anti-pd-1 bispecific antibody
WO2025042997A1 (en) * 2023-08-21 2025-02-27 Agenus Inc. Methods of treating colorectal cancer using a combination of a ctla-4 inhibitor and a pd-1 inhibitor
CN121712807A (zh) * 2023-08-31 2026-03-20 江苏恒瑞医药股份有限公司 Ctla4/tigit结合蛋白及其医药用途
WO2026021409A1 (zh) * 2024-07-22 2026-01-29 宜明昂科生物医药技术（上海）股份有限公司 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148079A0 (en) * 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
HRP20131167T1 (hr) * 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CA2955676A1 (en) * 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US20160362489A1 (en) * 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
JP2018522887A (ja) * 2015-07-14 2018-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫チェックポイント阻害剤を使用する癌の処置法
WO2017021911A1 (en) * 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP3331919A1 (en) * 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US10358496B2 (en) * 2016-03-01 2019-07-23 Ralf Kleef Low dose immune checkpoint blockade in metastatic cancer
LT3463457T (lt) * 2016-06-02 2023-09-11 Bristol-Myers Squibb Company Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą
WO2017210624A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor
WO2017210637A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
SG11201910134SA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Also Published As

Publication number Publication date
MA51844A (fr) 2021-05-19
JP2021513540A (ja) 2021-05-27
CN119792515A (zh) 2025-04-11
WO2019160755A1 (en) 2019-08-22
BR112020015915A2 (pt) 2020-12-15
KR20200119845A (ko) 2020-10-20
EP3752193A4 (en) 2022-02-23
US20210047409A1 (en) 2021-02-18
RU2020129075A (ru) 2022-03-14
AU2019222517A1 (en) 2020-08-13
JP2024038250A (ja) 2024-03-19
CN111727056A (zh) 2020-09-29
EP3752193A1 (en) 2020-12-23
BR112020015915A8 (pt) 2023-01-31
AU2023208115A1 (en) 2024-01-18
CA3090996A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
MX2024000780A (es) Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon.
CR20200467A (es) Agentes anticuerpos anti-cd25
MX2025008444A (es) Uso de un anticuerpo anti-pd-1 y un anticuerpo anti-cd3 x muc16 biespecifico para el tratamiento de un tumor que expresa muc16
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2024009277A (es) Anticuerpos anti proteina de muerte programada 1 (pd-1) y usos de estos.
MX2020012567A (es) Anticuerpos anti-ox40 y metodos de uso.
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
GEP20207166B (en) Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use
MY191423A (en) Binding molecules specific for cd73 and uses thereof
RU2014147867A (ru) Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
MX2021004226A (es) Terapia combinada contra el cáncer.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2022006147A (es) Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1.
PH12022553181A1 (en) Anti-pd-1 antibodies
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
MY204733A (en) Anti-pd-l1 antibodies and use thereof
MX2022006148A (es) Metodos para tratamiento del cancer usando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tigit.